ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for ADCT-601 targeting AXL in pancreatic cancer, and advancing differentiated solid tumor research platform FY 2023 operating expenses decreased 21%1 year-over-year due to portfolio prioritization and operational efficiencies; $278.6M o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other jurisdic ...

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 day ...

The market expects ADC Therapeutics SA (ADCT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, ...

With patience, some of the most undervalued biotech stocks can create massive wealth.Look at ACADIA Pharmaceuticals (NASDAQ:ACAD), for example. At one point, it traded at 70 cents, as it developed treatment for Parkinson’s disease psychosis. Years later, it would hit a high of $45.10 for a win of about 6,300%. Most recently, and in far less time, CRISPR Therapeutics (NASDAQ:CRSP) exploded from a low of about $40 to a high of nearly $77.50. Even Corbus Pharmaceuticals (NASDAQ:CRBP) popped from about $5 to a ...

January’s payrolls report shows 353,000 jobs … wage growth accelerates … the biotech sector is on fire … will you play it for short- or long-term gains? … how Luke Lango and Eric Fry view itNo recession in sight.That’s the takeaway from this morning’s nonfarm payrolls report.It showed the U.S. economy added 353,000 jobs in January, destroying the Dow Jones estimate for 185,000.Similarly, the increase in average hourly earnings towered above estimates. It came in at 0.6% on the month, double what economists ...

ADC Therapeutics (ADCT) is a commercial-stage biotech company focused on developing novel antibody-drug conjugates (ADC) to treat patients with hematologic malignancies and solid tumors.Currently, ADC Therapeutics has only one marketed drug in its portfolio, Zynlonta, which the FDA approves to treat relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in the third or later-line setting.Management is also evaluating Zynlonta in combination with other agents and earlier lines of therapy. Apart f ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ADC Therapeutics SA (ADCT) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.ADC Therapeutics SA is a member of our Medical group, which includes 1077 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 dif ...

SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead.That was one clear takeaway from the JPMorgan Healthcare Conference in San Francisco, the nation's largest gathering of biotech and pharmaceutical executives, analysts and investors. During the four-day event, the biotech and pharmaceutical industry signaled its enthusiasm for antibody-drug conjugates, or ADCs, which deliver a cance ...

ZYNLONTA®1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023 LOTIS-7: Study of ZYNLONTA in combination with bispecifics cleared first dosing cohort​ with no DLT and with early signs of efficacy ADCT-601 (targeting AXL): Reached MTD and currently in dose optimization; Early signs of antitumor activity in both monotherapy and in combination Multiple data catalysts expected in 2024 and with a cash runway now expected into 4Q 2025 LAUSANNE, Switzerland, ...